{
    "4 14 2025": {
        "importantArticles": [
            {
                "headline": "We recently published a list of Jim Cramer Hints at a Bigger Agenda Behind Tariffs and Breaks Down These 7 Stocks. In this article, we are going to take a look at where Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) stands against other stocks that Jim Cramer discusses. In his latest appearance on CNBC\u2019s Squawk on the Street, Jim [\u2026]",
                "publication_date": "2025-04-14T19:35:10.000Z",
                "sentiment": "Neutral",
                "sentimentScore": "0.0",
                "source": "Insider Monkey",
                "ticker": "RXRX",
                "title": "Jim Cramer on Recursion (RXRX): \u201cThe AI Company That Has It \u2013 Backed by Jensen Huang and NVIDIA\u201d",
                "url": "https://finance.yahoo.com/news/jim-cramer-recursion-rxrx-ai-193510944.html"
            },
            {
                "headline": "Recursion Pharmaceuticals (RXRX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.",
                "publication_date": "2025-04-14T13:09:00.000Z",
                "sentiment": "Negative",
                "sentimentScore": "-0.1098",
                "source": "Zacks",
                "ticker": "RXRX",
                "title": "Strength Seen in Recursion Pharmaceuticals (RXRX): Can Its 27.7% Jump Turn into More Strength?",
                "url": "https://finance.yahoo.com/news/strength-seen-recursion-pharmaceuticals-rxrx-130900685.html"
            },
            {
                "headline": "Recursion Pharmaceuticals (RXRX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.",
                "publication_date": "2025-04-14T13:09:00.000Z",
                "sentiment": "Negative",
                "sentimentScore": "-0.1098",
                "source": "Zacks",
                "ticker": "RXRX",
                "title": "Strength Seen in Recursion Pharmaceuticals (RXRX): Can Its 27.7% Jump Turn into More Strength?",
                "url": "https://finance.yahoo.com/news/strength-seen-recursion-pharmaceuticals-rxrx-130900685.html"
            },
            {
                "headline": "We recently published a list of Jim Cramer Hints at a Bigger Agenda Behind Tariffs and Breaks Down These 7 Stocks. In this article, we are going to take a look at where Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) stands against other stocks that Jim Cramer discusses. In his latest appearance on CNBC\u2019s Squawk on the Street, Jim [\u2026]",
                "publication_date": "2025-04-14T19:35:10.000Z",
                "sentiment": "Neutral",
                "sentimentScore": "0.0",
                "source": "Insider Monkey",
                "ticker": "RXRX",
                "title": "Jim Cramer on Recursion (RXRX): \u201cThe AI Company That Has It \u2013 Backed by Jensen Huang and NVIDIA\u201d",
                "url": "https://finance.yahoo.com/news/jim-cramer-recursion-rxrx-ai-193510944.html"
            }
        ],
        "avgScore": -0.0549
    },
    "4 11 2025": {
        "importantArticles": [
            {
                "headline": "Shares of Recursion Pharmaceuticals (NASDAQ: RXRX) were skyrocketing around 20% higher as of 11 a.m. ET on Friday.  The big gain for the biotech stock came after the U.S. Food and Drug Administration (FDA) announced on Thursday that it plans to replace the use of animals in testing drugs with \"more effective, human-relevant methods,\" including artificial intelligence (AI) models.  What will the FDA's move mean for Recursion?",
                "publication_date": "2025-04-11T15:11:29.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.902",
                "source": "Motley Fool",
                "ticker": "RXRX",
                "title": "Why Recursion Pharmaceuticals Stock Is Skyrocketing Today",
                "url": "https://finance.yahoo.com/news/why-recursion-pharmaceuticals-stock-skyrocketing-151129734.html"
            },
            {
                "headline": "Julie Hyman and Josh Lipton take a closer look at some of today's trending tickers. Recursion Pharma (RXRX) stock surges after the Food and Drug Administration (FDA) announced plans to phase out some animal testing requirements. Intel (INTC) stock falls as tensions in the US-China trade war intensify. Five Below (FIVE) stock declines as China tariffs impact orders. To watch more expert insights and analysis on the latest market action, check out more Market Domination here.",
                "publication_date": "2025-04-11T19:47:42.000Z",
                "sentiment": "Negative",
                "sentimentScore": "-0.7951",
                "source": "Yahoo Finance Video",
                "ticker": "RXRX",
                "title": "Recursion Pharma rises, Intel & Five Below fall: Trending Tickers",
                "url": "https://finance.yahoo.com/video/recursion-pharma-rises-intel-five-194742139.html"
            },
            {
                "headline": "Julie Hyman and Josh Lipton take a closer look at some of today's trending tickers. Recursion Pharma (RXRX) stock surges after the Food and Drug Administration (FDA) announced plans to phase out some animal testing requirements. Intel (INTC) stock falls as tensions in the US-China trade war intensify. Five Below (FIVE) stock declines as China tariffs impact orders. To watch more expert insights and analysis on the latest market action, check out more Market Domination here.",
                "publication_date": "2025-04-11T19:47:42.000Z",
                "sentiment": "Negative",
                "sentimentScore": "-0.7951",
                "source": "Yahoo Finance Video",
                "ticker": "RXRX",
                "title": "Recursion Pharma rises, Intel & Five Below fall: Trending Tickers",
                "url": "https://finance.yahoo.com/video/recursion-pharma-rises-intel-five-194742139.html"
            },
            {
                "headline": "Shares of Recursion Pharmaceuticals (NASDAQ: RXRX) were skyrocketing around 20% higher as of 11 a.m. ET on Friday.  The big gain for the biotech stock came after the U.S. Food and Drug Administration (FDA) announced on Thursday that it plans to replace the use of animals in testing drugs with \"more effective, human-relevant methods,\" including artificial intelligence (AI) models.  What will the FDA's move mean for Recursion?",
                "publication_date": "2025-04-11T15:11:29.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.902",
                "source": "Motley Fool",
                "ticker": "RXRX",
                "title": "Why Recursion Pharmaceuticals Stock Is Skyrocketing Today",
                "url": "https://finance.yahoo.com/news/why-recursion-pharmaceuticals-stock-skyrocketing-151129734.html"
            }
        ],
        "avgScore": 0.05345
    },
    "4 9 2025": {
        "importantArticles": [
            {
                "headline": "Kyiv, Ukraine and Salt Lake City, UT, April 09, 2025 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, today announced the generation of screening libraries leveraging tools within its AI/ML platform, the Recursion OS, with Enamine's REAL Space, the world\u2019s largest source of make-on-demand small molecules. Together, the two companies have curated 10 enriched screening libraries from over 15,000 newly synthesized co",
                "publication_date": "2025-04-09T12:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.4404",
                "source": "GlobeNewswire",
                "ticker": "RXRX",
                "title": "Recursion and Enamine Release New AI-Enabled Targeted Compound Libraries",
                "url": "https://finance.yahoo.com/news/recursion-enamine-release-ai-enabled-120000336.html"
            },
            {
                "headline": "Recursion Pharmaceuticals doses the first patient in a phase I study of its investigational candidate, REC-3565, for treating B-cell lymphomas.",
                "publication_date": "2025-04-09T14:01:00.000Z",
                "sentiment": "Neutral",
                "sentimentScore": "0.0",
                "source": "Zacks",
                "ticker": "RXRX",
                "title": "RXRX Doses First Patient in Early-Stage B-Cell Lymphomas Study",
                "url": "https://finance.yahoo.com/news/rxrx-doses-first-patient-early-140100723.html"
            },
            {
                "headline": "Recursion Pharmaceuticals doses the first patient in a phase I study of its investigational candidate, REC-3565, for treating B-cell lymphomas.",
                "publication_date": "2025-04-09T14:01:00.000Z",
                "sentiment": "Neutral",
                "sentimentScore": "0.0",
                "source": "Zacks",
                "ticker": "RXRX",
                "title": "RXRX Doses First Patient in Early-Stage B-Cell Lymphomas Study",
                "url": "https://finance.yahoo.com/news/rxrx-doses-first-patient-early-140100723.html"
            },
            {
                "headline": "Kyiv, Ukraine and Salt Lake City, UT, April 09, 2025 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, today announced the generation of screening libraries leveraging tools within its AI/ML platform, the Recursion OS, with Enamine's REAL Space, the world\u2019s largest source of make-on-demand small molecules. Together, the two companies have curated 10 enriched screening libraries from over 15,000 newly synthesized co",
                "publication_date": "2025-04-09T12:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.4404",
                "source": "GlobeNewswire",
                "ticker": "RXRX",
                "title": "Recursion and Enamine Release New AI-Enabled Targeted Compound Libraries",
                "url": "https://finance.yahoo.com/news/recursion-enamine-release-ai-enabled-120000336.html"
            }
        ],
        "avgScore": 0.2202
    },
    "4 8 2025": {
        "importantArticles": [
            {
                "headline": "REC-3565 is a potential best-in-class MALT1 inhibitor for multiple hematology indications, designed to reduce the risk of hyperbilirubinemia, a common side effect of other MALT1 inhibitorsSalt Lake City, UT, April 08, 2025 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, today announced that the first patient has been dosed in the Phase 1 EXCELERIZE clinical study evaluating REC-3565 for the treatment of relapsed",
                "publication_date": "2025-04-08T12:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.128",
                "source": "GlobeNewswire",
                "ticker": "RXRX",
                "title": "Recursion Announces First Patient Dosed in Phase 1 Clinical Study of REC-3565, a Selective MALT1 Inhibitor for Relapsed or Refractory B-cell Lymphomas",
                "url": "https://finance.yahoo.com/news/recursion-announces-first-patient-dosed-120000229.html"
            },
            {
                "headline": "REC-3565 is a potential best-in-class MALT1 inhibitor for multiple hematology indications, designed to reduce the risk of hyperbilirubinemia, a common side effect of other MALT1 inhibitorsSalt Lake City, UT, April 08, 2025 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, today announced that the first patient has been dosed in the Phase 1 EXCELERIZE clinical study evaluating REC-3565 for the treatment of relapsed",
                "publication_date": "2025-04-08T12:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.128",
                "source": "GlobeNewswire",
                "ticker": "RXRX",
                "title": "Recursion Announces First Patient Dosed in Phase 1 Clinical Study of REC-3565, a Selective MALT1 Inhibitor for Relapsed or Refractory B-cell Lymphomas",
                "url": "https://finance.yahoo.com/news/recursion-announces-first-patient-dosed-120000229.html"
            }
        ],
        "avgScore": 0.128
    },
    "coef": 0.39999999999999997,
    "avgCoef": 0.17835701548770636
}